Our top pick for
Hutchison China MediTech Limited is a biotechnology business based in the US. Hutchison China MediTech shares (HCM) are listed on the NASDAQ and all prices are listed in US Dollars. Hutchison China MediTech employs 1,280 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$19.77 - $37.00|
|50-day moving average||$28.75|
|200-day moving average||$30.90|
|Wall St. target price||$40.01|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.66|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$228 million|
|Gross profit TTM||$-135,319,000|
|Return on assets TTM||-20.67%|
|Return on equity TTM||-27.77%|
|Market capitalisation||$4.3 billion|
TTM: trailing 12 months
There are currently 829,953 Hutchison China MediTech shares held short by investors – that's known as Hutchison China MediTech's "short interest". This figure is 2.2% down from 848,568 last month.
There are a few different ways that this level of interest in shorting Hutchison China MediTech shares can be evaluated.
Hutchison China MediTech's "short interest ratio" (SIR) is the quantity of Hutchison China MediTech shares currently shorted divided by the average quantity of Hutchison China MediTech shares traded daily (recently around 146118.48591549). Hutchison China MediTech's SIR currently stands at 5.68. In other words for every 100,000 Hutchison China MediTech shares traded daily on the market, roughly 5680 shares are currently held short.
However Hutchison China MediTech's short interest can also be evaluated against the total number of Hutchison China MediTech shares, or, against the total number of tradable Hutchison China MediTech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Hutchison China MediTech's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Hutchison China MediTech shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Hutchison China MediTech shares, roughly 0 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Hutchison China MediTech.
Find out more about how you can short Hutchison China MediTech stock.
We're not expecting Hutchison China MediTech to pay a dividend over the next 12 months.
Hutchison China MediTech's shares were split on 29 May 2019.
Over the last 12 months, Hutchison China MediTech's shares have ranged in value from as little as $19.77 up to $37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Hutchison China MediTech's is 0.6711. This would suggest that Hutchison China MediTech's shares are less volatile than average (for this exchange).
Hutchison China MediTech Limited, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It offers research and development services; and manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company is developing Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma and soft tissue sarcoma, neuroendocrine neoplasms, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company is developing HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. Hutchison China MediTech Limited has collaboration agreement with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.